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Abstract
Despite advances in pharmacological treatments aimed at a neurohormonal blockade for heart
failure, there is still a growing number of patients with advanced symptoms who suffer signifi-
cant morbidity and mortality. At present the most effective cure for end-stage congestive heart
failure is cardiac transplantation. This method is severely limited owing to a lack of available
organs. This is why ventricular assist devices (VADs) capable of completely supporting the
circulation are taking on an increasingly important role in heart failure therapy. VADs are
important bridges to cardiac transplantation. The Randomised Evaluation of Mechanical
Assistance for the Treatment of Congestive Heart Failure (REMATCH) trial revealed that they
could be used as long-term destination therapy for non-transplant candidates. The latest
studies show that VAD support may also function as a bridge to ventricular recovery and
enable this procedure to take place. Apart from foreign devices, there is the Polish system
(PCAS), which is being prepared for introduction into global practice. (Cardiol J 2007;
14: 14–23)
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Introduction
Heart failure is now acknowledged to be the
most common malignant disease in industrialised
countries, with advanced heart failure having
a worse prognosis than most forms of cancer [1].
Advances in pharmacological treatment have helped
patients in all stages of systolic dysfunction, even
those with NYHA IV symptoms [2–4]. The Work-
ing Group on Heart Failure of the European Socie-
ty of Cardiology has promoted a number of initia-
tives aimed at improving the treatment of heart fail-
ure [5]. However, even the best combination of ACE
inhibition, b-blockade and diuretics is only able to
confer a survival benefit up to 16% at one year, and
this benefit disappears by year five [6]. Mechanical
stresses on the myocardium (increased preload and
afterload) and chronic neurohormonal activation
conspire to propagate the maladaptive ventricular
remodelling responsible for the insidious nature of
heart failure. Recent studies suggest that further
pharmacological neurohormonal blockade may be
neither safe nor effective [7]. This finding has led
to the concept that the limit to which neurohormo-
nal and cytokine mechanisms can be blocked in
heart failure patients has already been reached [8].
The problem of how to treat patients worldwide who
develop advanced heart failure despite optimal med-
ical therapy has not yet been resolved [9].
Transplantation provides the most effective
therapy for this condition, but the shortage of donor
organs has resulted in the US of fewer than 10% of
15
Agata Bielecka et al., The ventricular assist device
www.cardiologyjournal.org
potential recipients actually receiving a transplant [10].
This situation has forced scientists to search for
alternative methods of treatment. At present end-
stage chronic heart failure is a significant clinical
problem as well as a subject of scientific interest.
Transplant candidates whose disease reaches
its final stage before an appropriate donor heart
becomes available might be considered eligible for
temporary or permanent mechanical circulatory
support (MCS). The concept of circulatory assist-
ance is not new. The need for such temporary sup-
port for hours or days has been recognised for over
60 years and still exists [11]. It is recognised that
device-based approaches, ranging from the use of
devices for monitoring patient status in order to
anticipate exacerbation of congestive heart failure
and pre-emptively adjust therapy to the application
of devices for supporting preterminal patients with
end-stage disease, will assume an increasingly im-
portant role in treating the growing number of pa-
tients with advanced heart failure [12].
MCS was first used clinically in 1953 with the
implementation of cardiopulmonary bypass [13].
This breakthrough led to numerous surgical treat-
ments for a variety of cardiac disorders. The suc-
cess of cardiopulmonary bypass stimulated research
into other innovative techniques for supporting the
circulation. Counterpulsation with the intra-aortic
balloon pump was first applied clinically in 1967 to
support patients with acute heart failure [14].
Since 1953 congestive heart failure patients
were occasionally supported temporarily by cardio-
pulmonary bypass [15], an implantable ventricu-
lar assist device (VAD) [16] or a totally artificial
heart (TAH) [17]. Although the overall success rate
was limited, this early experience did prove that
MCS could adequately sustain a patient’s circulation
until cardiac function recovered or a donor heart
could be obtained. In the early 1980s the introduc-
tion of cyclosporine-based immunosuppression al-
lowed heart transplantation to become a widely ac-
cepted therapeutic alternative. During the same
decade clinical trials were initiated to evaluate the
safety and efficacy of MCS systems in supporting
terminally ill transplant candidates until a suitable
donor heart could be found. The use of a wearable
ventricular assist device (VAD) in the treatment of
advanced heart failure has steadily increased since
1993, when these devices became generally avail-
able in Europe.
Devices for the treatment of heart failure
Numerous devices are now approved by the
Food and Drug Administration (FDA) for therapy
in acute heart failure and in chronic decompensat-
ed congestive heart failure. We would like to focus
attention on the ventricular assist device used as
a bridge to transplant and, most recently, as desti-
nation therapy in patients ineligible for transplan-
tation [18]. These devices can be divided accord-
ing to site of placement (commonly extra-, para- or
intra-corporeal) and type of flow generator system
(centrifugal, axial or diaphragm). A left ventricular
assist device is shown diagrammatically in Figure 1.
VADs — indications for support
Because of the limited availability of donor or-
gans and the urgency of cardiac support in settings
of severe haemodynamic decompensation ventricu-
lar assist devices capable of completely supporting
the circulation are taking on an increasingly impor-
tant role in heart failure therapy.
MCS is life saving in patients who fail to im-
prove or stabilise with intravenous inotropes or
vasodilators, intra-aortic balloon-pump support and
mechanical ventilation [19].
Haemodynamic criteria for VAD insertion are
as follows:
— cardiac index < 2 L/min/m2;
— systolic blood pressure < 90 mm Hg;
— pulmonary capillary wedge > 20 mm Hg;
— urine output < 20 ml/h.
When these are found despite pharmacological sup-
port, optimal fluid loading and use of IABP as
Figure 1. The diagram of the left ventricular assist device.
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appropriate. Each case is assessed individually and
these criteria are used as a guide only. Some pa-
tients have the VAD inserted prior to these crite-
ria being met [20].
In planning the application of the assist device
we must decide whether one or both ventricles re-
quire support. Insertion of an implantable VAD com-
plicated by early right ventricular failure has a poor
prognosis and is largely unpredictable. Patients with
risk factors for right ventricle dysfunction (the need
for circulatory support, female gender, non-ischae-
mic aetiology) may best be treated with a biven-
tricular assist device or a TAH [21].
The next questions arising are whether the
VAD should be implanted as a bridge to transplan-
tation or as destination therapy and how long me-
chanical support will be required.
Selection of the appropriate device depends
on a number of considerations, including the an-
ticipated duration of patient support, the need for
right-side support and the patient’s size. Exclud-
ing of the strict contraindications to VAD, inser-
tion is very important.
The following are contraindications to VAD
insertion:
— irreversible hepatic/renal failure;
— active systemic infection;
— chronic obstructive airway disease;
— carcinoma with metastases;
— significant blood dyscrasias;
— cerebral vascular disease.
Ventricular assist devices
There are currently five FDA-approved VADs
in addition to the intra-aortic balloon pump. Extra-
corporeal devices include the ABIOMED BVS 5000
and Thoratec, which are both capable of biventricu-
lar assistance. Novacor N1000PC (World Heart
Corp), HeartMate Pneumatic (Thoratec  Corp), and
the Vented Electric LVADs are implantable devic-
es designed for left ventricular support.
The next generation of devices consists of axial
flow pumps with a non-pulsatile flow, totally implant-
able LVADs (Arrow LionHeart, WorldHeart Heart
Saver) with transcutaneous energy transfer and the
Total Artificial Heart (CardioWest, AbioCor).
At present devices are being used for univen-
tricular or biventricular support (Fig. 2). For left
support the inflow cannula is placed in either the
left atrial appendage, the left atrium via the intera-
trial groove or the left ventricular apex. The out-
flow cannula returns blood to the ascending aorta.
For right heart support atrial cannulation is used
with the outflow cannula returning blood to the
pulmonary artery.
Extracorporeal devices
The ABIOMED BVS 5000 consists of two ex-
tracorporeal pneumatic pulsative pumps that can be
used for univentricular or biventricular support. The
advantages of this support system are its ease of use
Figure 2. Diagram shows the Thoratec device used as a univentricular or biventricular assist device (From Farrar DJ,
Hill JD, Gray LA et al. N Engl J Med, 1988; 318: 333).
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and availability. It is typically used for periods up
to seven days.
The thoratec paracorporeal pump is a pneumat-
ically driven polyurethane sac designed for long-
term use. The Thoratec VAD system is indicated
as a bridge to transplantation and a bridge to recov-
ery. The main advantages of this device include its
versatility for biventricular support and its suitabil-
ity for use in small patients. Patients require anti-
coagulation for the duration of the Thoratec VAD
implantation.
Intracorporeal devices
The HeartMate LVAD is typically implanted in
a preperitoneal pocket (it can also be in an abdom-
inal location) anterior to the posterior rectus sheath
and just below the left costal margin. There are two
types of HeartMate device:
— the Implantable Pneumatic LVAD (IP-LVAD,
Thoratec Corp) is powered and controlled by
an external pneumatic drive console that rests
on a wheeled cart;
— the Vented Electric LVAD (VE-LVAD) con-
tains an electrical motor within the blood-pump
housing. It receives external power and control
signals from an external microprocessor via
a vented driveline.
Both systems have porcine valves and textured
blood-contacting surfaces that become covered by
a “pseudoneointimal” layer. This results in a very
low incidence of thromboembolic events, and there-
fore patients do not require systemic anticoagula-
tion. An increasing number of patients are being
discharged from hospital after implantation of the
VE-HeartMate. Insertion of the HeartMate is diffi-
cult in patients with a body surface area (BSA) less
than 1.5 m2 because of anatomical constraints.
The Novacor is an implantable electrical dual
pusher plate device designed for long-term cardiac
support. Like the HeartMate, it can be used only
for left-side support and in patients with a weight
of over 60 kg. The device has a percutaneous lead
that serves as both a vent and an electrical connec-
tion. The Novacor LVAD device requires systemic
anticoagulation to prevent thromboembolism. Even
with this, however, the risk of thromboembolic com-
plications with the Novacor LVAD remains high [22].
The advantages of this system are the excellent
mechanical reliability and successful outpatient
experience.
The Arrow Lionheart-2000 is an experimental
LVAD. The battery, controller and a gas compliance
chamber are implanted with no lines crossing the
skin. The pump is powered by means of continu-
ous transcutaneous energy transfer that maintains
the charge on the battery. The battery can operate
the device for approximately one hour when not
being charged, but only 20–30 min daily is recom-
mended. The device was designed for destination
therapy [12].
Device selection
Device selection depends not only on specific
patient characteristics and the pathology of the pa-
tient’s heart failure but also on device characteris-
tics, device availability and the experience of the
surgical team [23, 24]. Patients in profound cardio-
genic shock require support to avoid permanent
end-organ dysfunction and increase their chances
of survival. The preferred devices are the ABIO-
MED BVS 5000 or Thoratec device. These devices
may provide full biventricular support, re-establish-
ing near normal haemodynamics while myocardial
recovery is awaited. If prolonged support is expect-
ed, conversion to a longer-term device such as an
implantable LVAD or TAH should be considered.
The Thoratec device has the advantage of provid-
ing long-term, extracorporeal support.
Device selection for long-term support is much
more complicated and is often subjective and based
on the surgeon’s experience. For smaller patients
(BSA < 1.5 m2) the Thoratec device and perhaps
a continuous flow pump are the only options. For
the larger patient all devices are potential options.
An implantable LVAD is used most frequently, but
the CardioWest (now renamed “Syncor”) is useful
for severe biventricular failure. The role of the con-
tinuous flow pump remains to be defined. Current-
ly there is no approved device to provide permanent
MCS, although an FDA advisory panel has recom-




The newest generation of devices includes
axial flow and centrifugal pumps. The most mod-
ern axial flow devices offer significant potential ad-
vantages over earlier devices, because they are
smaller, simpler and less obtrusive to the patient,
yielding a better quality of life. The blood flow is
essentially non-pulsative and pump output is de-
pendent mainly on afterload. In addition, because
of their smaller size, they can be used in smaller
patients, including children [25]. Two axial flow
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pumps are in current use: the MicroMed/DeBakey
VAD (MM-D VAD) and the Jarvik 2000 Heart, which
have certain similarities in design and function.
The Jarvik 2000 Heart, in particular, has many
advantages. Its implantation can be performed with-
out median sternotomy, which makes the eventual
transplantation operation easier. There is no inflow
cannula, which rids the patient of the thrombotic and
haemolytic problems encountered with inflow can-
nulae. Circulation to the coronaries, the brachio-
cephalic, the left carotid and the subclavian arter-
ies is thus provided by retrograde flow. There is no
need for an external pocket in the mediastinum or
the peri-peritoneum, which decreases the risk of
infection [26]. Figure 3 shows the Jarvik 2000 pump
in the ventricular apex.
The MicroMed/DeBakey VAD consists of
a titanium inflow cannula that is inserted into the
left ventricular apex and leads to the pump proper,
which connects to the ascending aorta via a vascu-
lar graft. The pump is implanted through a median
sternotomy in a small extracardiac pocket [27].
The HeartMate II LVAD is an axial flow pump
that has a spinning rotor as its only moving part.
The HeartMate II has a left ventricular apical in-
flow cannula with a sintered titanium blood-contain-
ing surface. No compliance chamber or valves are
necessary. The outflow cannula is connected to
a Dacron graft, which is then anastomosed to the
ascending aorta in a similar fashion to that achieved
with the original HeartMate XVE. The pump is
designed to deliver as much as 10 L/min of cardiac
output and is placed either intraperitoneally or
extraperitoneally [28, 29]. The HeartMate II LVAD
is shown in Figure 4.
Centrifugal pumps
Centrifugal pumps utilise the pump mechanism
of a standard heart bypass. Two of the most com-
mon are the Medtronic-Biomedicus pump and in-
tracorporeal devices, while the latest extracorpor-
eal centrifugal pumps are becoming increasingly
popular. New centrifugal systems include the bear-
ingless system. This drive system is magnetically
coupled to an external power source and pump flow
is related to rotation speed. The advantages of the
centrifugal pump are simplicity of design, versatil-
ity and the relatively low costs of manufacture and
operation. It can be used as a femoral-femoral by-
pass or as a left (right) ventricular-to-aortic (pul-
monic artery) bypass. Its main disadvantages are
the need for heparinisation, difficulty in chest clo-
sure, the need for intensive monitoring and the in-
ability to generate a pulsatile flow. The pump is used
primarily as a bridge to recovery in cardiogenic
shock. The total duration of support with a centrif-
ugal pump is usually limited to no more than two to
three weeks [30].
Intracorporeal centrifugal devices
The Ventrassist implantable rotary blood pump
is a hydrodynamically suspended electromagneti-
cally driven centrifugal blood pump that provides
a continuous flow of up to 10 L/min at a low rotation-
al speed and power consumption level [31].
The HeartQuest ventricular assist device is
an advanced device with full magnetic suspension
of the rotor designed to address specific clinical
shortcomings in existing devices and to maximise
Figure 4. HeartMate II left ventricular assist device.
Figure 3. The Jarvik 2000 pump in the ventricular apex.
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margins of safety and performance for an implanta-
ble assist device. The dimensions of this device are
35 × 75 mm and it has a total weight of 440 g. Ani-
mal study results have been very promising with
clean surfaces seen in a 116-day experiment and no
anticoagulation after day 43 [32].
The extracorporeal centrifugal pump
The Levitronix Centrimag short-term ven-
tricular assist device is a centrifugal pump designed
for extracorporeal short-term support that operates
without mechanical bearings and seals. The rotor
is magnetically levitated so that rotation is achieved
without friction or wear, which seems to minimise
blood trauma and mechanical failure [33].
Percutaneous assist devices
Some of the new percutaneous assist devices
(pVADs) are currently being explored in clinical
trials. The TandemHeart pVAD is a continuous-flow
centrifugal pump designed to provide up to 4.0 L/min
of systemic blood flow. The pump requires a prim-
ing volume of 10 mL. The device can be rapidly in-
serted in the catheterisation laboratory using
a standard trans-septal approach. The inflow cannu-
la is inserted into the femoral vein and is advanced
across the interatrial septum into the left atrium. The
outflow cannula returns oxygenated blood to the
femoral artery. The Cancion system consists of
a centrifugal pump connected to the circulation via
a graft cannula anastomosed to the left axillary artery
and a percutaneous cannula placed into the left com-
mon femoral artery. Flow is initiated from the fem-
oral to the axillary artery. The Impella Recover 100
is a new intravascular microaxial blood pump for use
as short-term mechanical support for cases of acute-
ly reduced left ventricular function. These systems
have quickly and effectively improved the patient’s
haemodynamics, suggesting that they may one day
become a short-term alternative to high-dose ino-
trope therapy and that their application may delay
the need for more invasive forms of mechanical cir-
culatory support [34–36].
Total artificial hearts
Ventricular assist devices support the fail-
ing heart by bypassing one or both ventricles.
In certain cases, such as myocardial tumours,
graft failure, transplant rejection, endocarditis
and intracardiac thrombus formation, it may be
advantageous to excise the heart and replace it
with an artificial device. Total artificial hearts
are intracorporeal devices designed for this
purpose. Two of these kinds of device are cur-
rently in use.
The AbioCor Artificial Heart (new name) is
completely implantable in the orthotopic position
and has an internal battery and a transcutaneous
energy transfer system that enables the battery to
be recharged or the device to be run with an exter-
nal coil (Fig. 5).
The CardioWest Total Artificial Heart was re-
cently approved for use under an FDA investigational
device exemption. This device is pneumatically driv-
en and is implanted in the orthotopic position. Dual
pneumatic drivelines exit transcutaneously to a con-
sole control system that monitors pump pressures
and performance. Antiplatelet and systemic anti-
coagulation are needed. This device is used as
a bridge to transplantation in patients with biven-
tricular failure [37].
Total artificial heart pumps are too large to be
completely implanted in children or other patients
with body surfaces smaller than 1.7 m². In these
smaller patients extracorporeal devices must be
used for biventricular assistance.
Ventricular assist devices
in clinical studies
The use of left ventricular assist devices
(LVADs) as an alternative to heart transplantation
Figure 5. Diagram of the AbioCor Artificial Heart.
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(destination therapy) is on the clinical threshold.
The Randomised Evaluation of Mechanical Assist-
ance for the Treatment of Congestive Heart Fail-
ure (REMATCH) trial compared medical treatment
with the electrically driven HeartMate device
(Thoratec  Corp) in functional class IV patients who
were not heart transplantation candidates. Survival
in the LVAD group was equal to or better than that
in those with medical management at all time points
after randomisation for patients undergoing baseline
inotropic therapy. By six months survival in this
population was 60% with LVAD compared to 39%
without. At one year survival was doubled by LVAD:
49% compared to 24% without. By two years sur-
vival with LVADs was 28% compared with 11% for
current medical therapy [38]. In addition, Mancini
et al. [39] have recently demonstrated that LVAD
patients can achieve a near-normal exercise re-
sponse, equivalent to that of patients with mild heart
failure, and Dew et al. [40] have shown that patients
with a LVAD enjoy a quality of life that is compara-
ble to that of transplant recipients.
Experience with MCS has been gained mainly
with patients who are being supported temporarily
and for whom it is a bridge to transplantation. One
important observation during this experience has
been that some hearts recovered sufficient function
to have the device removed. For example, the ma-
jority of Novacor applications have been employed
as a bridge to transplantation, but a growing number
of patients are now implanted with a view to recov-
ery of native left ventricular function. A recent sin-
gle-centre publication has demonstrated that as
many as 24% of supported patients may recover
sufficient ventricular function to allow them to be
weaned from the LVAD [41].
In a study conducted in Pittsburgh VAD as
a bridge to recovery was seen in 6.5% of cases over-
all and in 11% of non-ischaemic patients and was
most successful with acute inflammatory cardiomy-
opathy or post-partum cardiomyopathy [42]. The
bridge to recovery is most successful in patients
with postsurgical cardiac failure, acute myocarditis
and AMI.
However, Dandel’s et al. study [43] showed
that restoration of heart size and function can be ob-
tained by LVAD support even in patients with ad-
vanced idiopathic dilated cardiomyopathy, a disease
that, until recently, was considered to be almost
irreversible. This research revealed that for selected
patients with idiopathic dilated cardiomyopathy wean-
ing from LVADs is a clinical option with good results
over nine years and should be considered in those with
cardiac recovery after LVAD implantation.
The potential reversibility of myocyte contrac-
tile defects is suggested by studies in which isolat-
ed failing myocytes obtained from hearts that had
been supported with a LVAD manifested improved
shortening and relaxation compared with myocytes
isolated from hearts that had not been supported
with a LVAD [44]. Although this interesting study
did not directly address the mechanism for this find-
ing, two recent studies may provide a partial expla-
nation. In the first study support with a LVAD was
shown to improve the force-frequency relationship
of isolated strips of ventricular tissue and bring
about improvements in gene encoding for proteins
involved in Ca2+ handling (sarcoplasmic reticulum
calcium ATPase, the ryanodine receptor, and the
sarcolemmal sodium-calcium exchanger) [45]. In
the second study LVAD support led to a restora-
tion of the integrity of the dystrophin cytoskeleton,
which had been shown to be disrupted in myocytes
from failing hearts [46].
Given the shortage of donor organs, all patients
undergoing MCS should be systematically evaluat-
ed for evidence of myocardial recovery [47, 48].
Future medical therapies are now being tested.
Researchers at the University of Pittsburgh
Medical Center injected stem cells obtained from
each patient’s own bone marrow into between five
and ten heart-failure patients from the time of im-
plantation with a LVAD to heart transplantation.
According to the lead investigator, Dr. Amit Patel,
the purpose of the new trial is to place the stem cells
into the areas of damaged cardiac tissue and then,
when the heart is removed to be replaced with
a donor organ, to see what has taken place.
In Patel’s new study in the USA a portion of
heart muscle will be injected with 25 million to
45 million stem cells that have been isolated from
the patient’s own bone marrow. Ordinary blood
serum will be injected into another portion of the
tissue for purposes of comparison. The procedures
will be performed when the patient receives the
assist device to bolster heart pumping. As well as
taking various measurements, the researchers will
reduce the output of the heart pump about three
months after implantation to see if the heart is re-
covering. The diseased heart will be removed when
a donor organ is available for transplant, perhaps six
to nine months later, so that the impact of the in-
jected cells may be seen. Researchers suspect that
the stem cells, which have the ability to generate
specialised cells, could produce cardiac cells and
new blood vessels in impaired tissue, and it is like-
ly that some cells will fuse with weakened heart
cells [49].
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An alternative mode of treatment involves the
use of clenbuterol (a b2 agonist) for the improve-
ment of cardiac function and exercise capacity in
LVAD patients. The process of reverse remodel-
ling of the unloaded left ventricle must be studied
in prospective multicentre trials.
The artificial heart could, according to the Car-
diosurgical Development Foundation in Zabrze,
save the life of several thousand patients a year.
Foreign devices are extremely expensive and
Polish ones may be as good but much cheaper. The
Polish cardiac assist system (PCAS) consists of an
extracorporeal ventricular assist device (POLVAD II),
a complete heart prosthesis (POLTAH II) and
heart-supporting ventricles (PCAS DU 401). At
present the system is being prepared for introduc-
tion into global practice (Figs. 6–9).
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